Higher versus standard immunoglobulin dosing to slow airway disease progression in primary antibody deficiency

Phase 4, randomised trial of polyvalent human immunoglobulin in Primary antibody deficiency (PAD) and common variable immunodeficiency (CVID) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Change in airway disease and interstitial lung disease CT scores over 2 years. Started Aug 2022; status: active, not recruiting.